GLP-1s do not cause major psychiatric harm, according to new study
Tuesday, September 1 – There is no link between the widely used diabetes and obesity medications known as GLP-1 receptor agonists and increased suicidal thoughts, depression or other serious psychiatric harm, based on an integrative review of current scientific evidence conducted by researchers at New Mexico State University and the University of Nevada, Las Vegas.
GLP-1 Drugs Tied to Gallbladder and Biliary Risks in Youth
Tuesday, September 1 – (MedPage Today) — Use of GLP-1 receptor agonists was associated with increased cumulative gallbladder and biliary events in youths, according to a retrospective analysis of TriNetX data.
Among over 37,000 adolescents and young adults with overweight…
GLP-1 Studies Suggest Benefits Extend to Infectious Diseases
Tuesday, September 1 – (MedPage Today) — Recent studies suggest that people with type 2 diabetes on GLP-1 receptor agonists were less likely to develop tuberculosis (TB) or be hospitalized or die from infections.
In an international study of more than 7 million people…
Court: No harm done when GLP-1s dropped from FDA shortage list
Tuesday, September 1 – Since the Federal Food, Drug and Cosmetics Act requires the U.S. FDA to maintain an updated list of prescription drugs that are in shortage, does the FDA have to go through months of a notice-and-comment rulemaking before it can remove a drug from the list when the agency determines it’s no longer in short supply? The U.S. Court of Appeals for the Fifth Circuit danced around that question even as it upheld a lower court’s summary judgment shutting down compounders’ challenges to the FDA removing Eli Lilly and Co.’s and Novo Nordisk A/S’ popular GLP-1 drugs from the shortage list in October 2024.
STAT+: GLP-1 drugs are almost single-handedly forcing employers to reconsider workers’ health care
Tuesday, September 1 – Another hospital system sues CVS Health, how Medicaid cuts will change everything, and more
Trump’s Latest Name For GLP-1s Has Doctors And Patients Raising An Important Concern
Sunday, August 30 – Despite the president’s comments, patients say these medications have been life-changing, and their effectiveness cannot be ignored.
About a Quarter of Those Who Stop Wegovy Start Again
Saturday, August 29 – (MedPage Today) — Nearly half of adults who started semaglutide (Wegovy) for obesity management stopped treatment within a year, a Danish cohort study showed.
Among 157,822 first-time semaglutide initiators without diabetes, 49% discontinued…
Mounjaro scores FDA approval to reduce CV risk; Teva to buy an approved drug
Saturday, August 29 – Plus news about AusperBio and Samsung Biologics.
Eli Lilly’s Mounjaro wins heart approval: The blockbuster drug, whose generic name is tirzepatide, was approved on Friday to reduce the risk of major …
Lilly joins Novo in cardiovascular space after FDA nod for GLP-1/GIP agonist Mounjaro
Saturday, August 29 – With the approval, Eli Lilly’s Mounjaro becomes the first dual GIP/GLP-1 receptor agonist indicated to lower the risk of heart attack, stroke or cardiovascular death in adults with type 2 diabetes.
5th Circ. Backs FDA, Pharma Cos. In GLP-1 Shortage Fight
Saturday, August 29 – The U.S. Food and Drug Administration did not unlawfully remove blockbuster GLP-1 medications made by Eli Lilly & Co. and Novo Nordisk from the national drug shortage list, the Fifth Circuit ruled Thursday, handing a loss to compounding pharmacies that produce copycat doses of the drugs.